When targeting a somatic cancer mutation in the TERT promoter, the approach presented here could provide the key advantage of reducing adverse side effects of anti-TERT treatments, since the TERT inhibition is specific for the cancer cells harboring the SNV target for the ASEE complex. The gene discussed is TERT; the disease is cancer.